サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1378892

神経バイオマーカー市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
神経バイオマーカー市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の神経バイオマーカー市場規模は2022年に79億米ドルに達しました。今後、IMARC Groupは、同市場が2028年までに164億米ドルに達し、2022年から2028年の間に12.9%の成長率（CAGR）を示すと予測しています。

神経バイオマーカーは、血液や脳脊髄液（CSF）中に存在する分子で、脳疾患の診断をサポートし、疾患の進行を監視します。これらのバイオマーカーの主な供給源は、遺伝子変異、代謝物レベル、脳画像、タンパク質発現や翻訳後修飾の変化です。バイオマーカーは実験薬に対する生物学的反応を検出し、治療介入のための新たな標的の発見に役立つため、神経バイオマーカーは医薬品開発中の臨床現場で広く用いられています。現在、研究者はバイオマーカー濃度を測定し、非侵襲的検査、早期診断、個別化治療を提供しています。

脳卒中、運動ニューロン疾患（MND）、アルツハイマー病（AD）、パーキンソン病（PD）、ハンチントン病（HD）などの神経疾患の発生が増加しており、より迅速な医薬品開発の必要性が高まっています。バイオマーカーは新薬や治療戦略の有効性を測定するのに役立つため、これは市場成長を促す主な要因の1つとなっています。また、低侵襲手術や個別化医療の採用が増加していることも、成長を促す大きな要因となっています。これとは別に、さまざまな神経疾患が標準的な特徴を共有しているため、特定の疾患やそのサブタイプを区別するための複数のバイオマーカーの需要が増加しています。さらに、質量分析と画像診断の進歩により、大量の生化学マーカーと脳の構造変化を迅速に評価できるようになっています。このことは、デジタルバイオマーカーのイントロダクションや臨床試験数の増加とともに、今後数年間の市場成長を促進すると予想されます。

本レポートで扱う主な質問

  • 神経バイオマーカーの世界市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が世界の神経バイオマーカー市場に与えた影響は？
  • 主要な地域市場は？
  • タイプ別の市場内訳は？
  • 用途別の市場内訳は？
  • 最終用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の神経バイオマーカー市場の構造と主要プレーヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 神経バイオマーカーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • ゲノムバイオマーカー
    • 市場動向
    • 市場予測
  • プロテオミクスバイオマーカー
    • 市場動向
    • 市場予測
  • メタボロームバイオマーカー
    • 市場動向
    • 市場予測
  • イメージングバイオマーカー
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • アルツハイマー病
    • 市場動向
    • 市場予測
  • パーキンソン病
    • 市場動向
    • 市場予測
  • 多発性硬化症
    • 市場動向
    • 市場予測
  • 自閉症スペクトラム
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：最終用途別

  • 病院検査室
    • 市場動向
    • 市場予測
  • 臨床診断センター
    • 市場動向
    • 市場予測
  • 調査機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Acumen Pharmaceuticals Inc.
    • Athena Diagnostics（Quest Diagnostics）
    • Banyan Biomarkers Inc.
    • Bio-Rad Laboratories Inc.
    • Immunarray Pvt. Ltd.
    • Myriad Rbm Inc.（Myriad Genetics Inc.）
    • Proteome Sciences Plc
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Neurological Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Neurological Biomarkers Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Neurological Biomarkers Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Neurological Biomarkers Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Neurological Biomarkers Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Neurological Biomarkers Market: Breakup by End Use (in %), 2022
  • Figure 7: Global: Neurological Biomarkers Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Neurological Biomarkers (Genomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Neurological Biomarkers (Genomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Neurological Biomarkers (Proteomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Neurological Biomarkers (Proteomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Neurological Biomarkers (Imaging Biomarkers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Neurological Biomarkers (Imaging Biomarkers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Neurological Biomarkers (Alzheimer's Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Neurological Biomarkers (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Neurological Biomarkers (Parkinson's Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Neurological Biomarkers (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Neurological Biomarkers (Multiple Sclerosis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Neurological Biomarkers (Multiple Sclerosis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Neurological Biomarkers (Hospital Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Neurological Biomarkers (Hospital Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Neurological Biomarkers (Research Organizations) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Neurological Biomarkers (Research Organizations) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: North America: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: North America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: United States: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: United States: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Canada: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Canada: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Asia-Pacific: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Asia-Pacific: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: China: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: China: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Japan: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Japan: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: India: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: India: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: South Korea: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: South Korea: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Australia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Australia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Indonesia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Indonesia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Europe: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Europe: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Germany: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Germany: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: France: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: France: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: United Kingdom: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: United Kingdom: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Italy: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Italy: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Spain: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Spain: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Russia: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Russia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Latin America: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Latin America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Brazil: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Brazil: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Mexico: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Mexico: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Middle East and Africa: Neurological Biomarkers Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Middle East and Africa: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Middle East and Africa: Neurological Biomarkers Market: Breakup by Country (in %), 2022
  • Figure 85: Global: Neurological Biomarkers Industry: SWOT Analysis
  • Figure 86: Global: Neurological Biomarkers Industry: Value Chain Analysis
  • Figure 87: Global: Neurological Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurological Biomarkers Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Neurological Biomarkers Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Neurological Biomarkers Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Neurological Biomarkers Market Forecast: Breakup by End Use (in Million US$), 2023-2028
  • Table 5: Global: Neurological Biomarkers Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Neurological Biomarkers Market: Competitive Structure
  • Table 7: Global: Neurological Biomarkers Market: Key Players
目次
Product Code: SR112023A3181

Abstract

The global neurological biomarkers market size reached US$ 7.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.4 Billion by 2028, exhibiting a growth rate (CAGR) of 12.9% during 2022-2028.

Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.

The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and end use.

Breakup by Type:

Genomic Biomarkers

Proteomic Biomarkers

Metabolomic Biomarkers

Imaging Biomarkers

Others

Breakup by Application:

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Autism Spectrum Disorders

Others

Breakup by End Use:

Hospital Laboratories

Clinical Diagnostic Centers

Research Organizations

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neurological biomarkers market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neurological biomarkers market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurological Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Genomic Biomarkers
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Proteomic Biomarkers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Metabolomic Biomarkers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Imaging Biomarkers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Alzheimer's Disease
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parkinson's Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Multiple Sclerosis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Autism Spectrum Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospital Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinical Diagnostic Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Organizations
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Acumen Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Athena Diagnostics (Quest Diagnostics)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Banyan Biomarkers Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Immunarray Pvt. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Proteome Sciences Plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Thermo Fisher Scientific Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis